GPhA Study Assails REMS Misuse to Delay Generics

Drug Industry Daily
A A
Brand manufacturers who use risk evaluation and mitigation strategies (REMS) to delay generic competition by denying product samples to would-be ANDA filers are costing pharmaceutical payers billions of dollars each year, according to a new study commissioned by GPhA.

To View This Article:

Login

Subscribe To Drug Industry Daily